Login
$GOSS
$10.98 +$0.01 (0.09%) Live

$GOSS SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

– New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 –

10 Nov 2026 10-Q
06 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 SCHEDULE 13G
29 Oct 2026 SCHEDULE 13D/A
28 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast for or against, the ...

08 Oct 2026 SCHEDULE 13D/A
28 Sep 2026 SCHEDULE 13D/A
28 Sep 2026 8-K: Other Events

On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price ...

25 Sep 2026 Form 4: Milligan Sandra, Director

Granted 10,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Daniel Thomas O, Director

Granted 10,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Ciongoli Gregory Austin, Director

Granted 30,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Drynan Skye, Director

Granted 10,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Quisel John D, Director

Granted 10,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Cox Russell J., Director

Granted 10,000 Stock Option (Right to Buy)

25 Sep 2026 Form 4: Nathan Steven D, Director

Granted 10,000 Stock Option (Right to Buy)

23 Sep 2026 8-K: Other Events

On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arteri...

22 Sep 2026 Form 3: Ciongoli Gregory Austin, Director
16 Sep 2026 DEF 14A
16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hype...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support